NEW YORK ( TheStreet) -- Human Genome Sciences Inc (Nasdaq: HGSI) hit a new 52-week low Tuesday as it is currently trading at $7.48, below its previous 52-week low of $7.50 with 2.1 million shares traded as of 2:06 p.m. ET. Average volume has been six million shares over the past 30 days. Human Genome Sciences has a market cap of $1.61 billion and is part of the health care sector and drugs industry. Shares are down 67.7% year to date as of the close of trading on Monday. Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter